A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 7, 2012, Pages 1303-1311

  Vavalle, J P ^a   Rusconi, C P ^b   Zelenkofske, S ^b   Wargin, W A ^c   Alexander, J H ^a   Becker, R C ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Regado Biosciences Inc   (United States)

^c PK PM Associates LLC   (United States)

Author keywords

Anticoagulant; Aptamer; Factor IX IXa inhibitor

Indexed keywords

ANIVAMERSEN; PEGNIVACOGIN; PLACEBO; REG 2; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULATION; ARTICLE; CALCULATION; COHORT ANALYSIS; CONTROLLED STUDY; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; METRORRHAGIA; MYALGIA; NAUSEA; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

ANTICOAGULANTS; APTAMERS, NUCLEOTIDE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR IXA; HUMANS; INJECTIONS, SUBCUTANEOUS; PLACEBOS;

EID: 84863465362     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04742.x     Document Type: Article

References (17)

1. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005; 3: 1843-53.
2. Eikelboom JW, Zelenkofske SL, Rusconi CP. Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol 2010; 30: 382-7.
3. Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost 2007; 5: 1106-12.
4. Howard EL, Becker KC, Rusconi CP, Becker RC. Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 2007; 27: 722-7.
5. Povsic TJ, Cohen MG, Chan MY, Zelenkofske SL, Wargin WA, Harrington RA, Alexander JH, Rusconi CP, Becker RC. Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design. J Thromb Thrombolysis 2011; 32: 21-31.
6. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Alexander JH, Harrington RA, Tonkens RM, Becker RC, Rusconi CP. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008; 117: 2865-74.
7. Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost 2008; 6: 789-96.
8. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, Fry E, Chan MY, Tonkens RM, Zelenkofske S, Alexander JH, Harrington RA, Rusconi CP, Becker RC. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 2010; 122: 614-22.
9. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, Alexander JH, Becker RC, Rusconi CP. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006; 114: 2490-7.
10. Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000; 89: 297-310.
11. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990; 7: 167-9.
12. Christopher P, Rusconi DK, Steven L. Zelenkofske. Subcutaneous FIXa Inhibitor Provides Prolonged Anticoagulation: The First Successful Subcutaneous Application of an Aptamer. Atlanta, GA: American College of Cardiology, 2010.
13. Povsic TJ, Wargin WA, Alexander JH, Krasnow J, Krolick M, Cohen MG, Mehran R, Buller CE, Bode C, Zelenkofske SL, Rusconi CP, Becker RC. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. Eur Heart J 2011; 32: 2412-19.
14. Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci 1964; 53: 1392-403.
15. Supersaxo A, Hein W, Gallati H, Steffen H. Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm Res 1988; 5: 472-6.
16. Charman SA, Segrave AM, Edwards GA, Porter CJ. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J Pharm Sci 2000; 89: 168-77.
17. McLennan DN, Porter CJH, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol 2005; 2: 89-96.